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Abstract
Anticoagulant rodenticides (ARs) are a keystone of the management of rodent popula-
tions in the world. The widespread use of these molecules raises questions on exposure 
and intoxication risks, which define the safety of these products. Exposures and intoxica-
tions can affect humans, domestic animals and wildlife. Consequences are different for 
each group, from the simple issue of intoxication in humans to public health concern if 
farm animals are exposed. After a rapid presentation of the mechanism of action and the 
use of anticoagulant rodenticides, this chapter assesses the prominence of poisoning by 
anticoagulant rodenticides in humans, domestic animals and wildlife.
Keywords: anticoagulant, rodent, poisoning
1. Introduction
The management of rodents around the world is a great concern, in many aspects. Rodents 
are ubiquitous and opportunistic animals, some such as the brown rats (Rattus norvegicus) and 
the black rats (Rattus rattus) are present at all continents except Antarctic [1]. These rodent 
populations are an ecological and an economic issue in the islands where they are not indig-
enous [2]. Agriculture is also affected by rodents; in France, for instance, water voles (Arvicola 
terrestris) devastate some lands [3]. Finally, rodents are a major nuisance in cities where their 
proximity to and interactions with human populations and infrastructure can cause impair-
ments and become a hazard for the public health as they are reservoirs of many diseases. In 
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China, rodents destroyed the rice stock that would be sufficient to feed 200 millions of people 
[4] and the estimation of the cost induced by rodents’ damage is about 19 billions of dollars 
[5]. Many similar cases have been recorded around the world [1, 6].
To deal with these concerns, rodent populations have to be controlled. One of the most used 
management methods is the chemical method based on the use of anticoagulant rodenticides 
(ARs). Anticoagulant rodenticides (ARs) have been used since the 1940s to control rodent 
populations. Warfarin was the first molecule used. But after its use for more than one decade, 
resistant strains of rodents to ARs have emerged [7]. To deal with resistance, this first genera-
tion of ARs has been supplemented by a second generation. ARs of the second generation are 
frequently named ’superwarfarins’ or long-acting anticoagulant rodenticides. Indeed, these 
molecules are more potent than the first generation due to their longer half-life, which implies 
longer tissue-persistence and better efficacy.
Indeed, the consequence of the widespread use of ARs and more specifically the second gen-
eration of ARs, that are more efficient and more persistent, has been an increase of the exposure 
risks and the intoxication risks for non-target species such as pets, wildlife as well as humans. 
Nevertheless, anticoagulant rodenticides are renowned as a safe method to manage rodent 
populations. This safety is due to their mechanism of action as well as on the implementation 
of good practices in their use and by the respect of related regulations. Beyond this renown, it is 
important to monitor the impact of using ARs regarding the risk of untargeted species poison-
ing and to discuss on the remaining grey area in our knowledge on anticoagulant rodenticides.
Hence, after a rapid presentation of the mechanism of action and the use of anticoagulant 
rodenticides, this chapter assesses the importance of the exposure and the intoxication by 
anticoagulant rodenticides.
2. Anticoagulant rodenticides
The current anticoagulant rodenticide molecules belong to the family of vitamin K antagonist 
(VKA) molecules. The effects of VKAs have been observed in the ‘sweet clover’ poisoning of 
bovines, which results in a haemorrhagic disease and often the death of the animal [8–10]. 
Clover (Melilotus officinalis), used as fodder, contains coumarin a precursor of dicoumarol 
which is a VKA (Figure 1E). If clover fodders are not stored under proper conditions, fermen-
tations may occur. These fermentations change clover coumarin in dicoumarol. Thus, clover 
fodder become toxic [10]. Dicoumarol was synthesised by Paul and Stahmann in 1941, open-
ing the opportunity of use VKA as medicine and rodenticide [11]. Then other VKA molecules 
have been synthesised, including the famous warfarin (Figure 1D) and all other products that 
are more potent than dicoumarol [12].
The main molecules used in the rodent population management are presented in Figure 1. 
VKA molecules are derived from a coumarin (Figure 1A), thiocoumarin (Figure 1B) or 
1,3-indandione (Figure 1C) core. The distinction of the second generation of AR from the 
first generation is the radical. In second generation, radical includes three benzene structures, 
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Figure 1. Chemical structure of: (A) coumarin core; (B) thiocoumarin core; (C) 1,3-indandione core; (D) warfarin; (E) 
dicoumarol; (F) coumatetralyl; (G) chlorophacinone; (H) bromadiolone; (I) difenacoum; (J) brodifacoum; (K) difethialone; 
and (L) flocoumafen.
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which increase the fat solubility of the molecules and influence their pharmacokinetic proper-
ties. In order to understand the interest of VKAs and the key issue of their safety, it is impor-
tant to present their mechanism of action and their pharmacokinetics.
2.1. Mechanism of action
Vitamin K antagonists (VKA) are non-competitive inhibitors of the vitamin K epoxide 
reductase enzyme (VKORC1) [13, 14]. This membrane enzyme of endoplasmic reticulum is 
responsible for the recycling of vitamin K. Vitamin K is a cofactor essential to many biotrans-
formations of proteins and more specifically to obtain an active form of some clotting fac-
tors, the factors II, VII, IX and X. These factors, called vitamin K-dependent clotting factors, 
have to go through a post-translational gamma-carboxylation of their glutamate residues into 
gamma-carboxyglutamic acid to be able to chelate calcium and have their physiological activ-
ity [15, 16]. This reaction is done by gamma-glutamyl carboxylase (GGCX), which is another 
membrane enzyme of endoplasmic reticulum, and needs the oxidation of vitamin K hydro-
quinone to vitamin K epoxide to provide the required reducing power [17, 18]. Then VKORC1 
recycles vitamin K epoxides to vitamin K hydroquinones (Figure 2) [19].
The amount of vitamin K provided by the majorities of food is not sufficient to offset the 
complete arrest of vitamin K cycle. Consequently, when VKORC1 is inhibited by VKA, a 
sufficient amount of vitamin K hydroquinone cannot be recycled from vitamin K epoxides 
to ensure the gamma-carboxylation of vitamin K-dependent proteins, and more especially 
the vitamin K-dependent clotting factors. Consequently, the blood concentrations of active 
vitamin K-dependent clotting factors decrease and lead to an increase of clotting times then, 
with time, to the death by haemorrhages.
2.2. Pharmacokinetics properties
Vitamin K antagonists are reputed to be highly and rapidly absorbed after per os adminis-
tration. Then they are mainly stocked in liver. Their liver storage and their elimination are 
Figure 2. Vitamin K cycle.
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key factors, which determine a part of their efficiency and their persistence. The elimina-
tion pathway depends on the molecule and on its enantiomeric form [20]. For example, 
enantiomers of warfarin are eliminated differently. The (S)-enantiomer is metabolised 
exclusively by the hepatic cytochrome P450 isoform 2C9 (CYP2C9) while (R)-enantiomer 
is metabolised by isoforms CYP1A2, CYP2C19, CYP3A and hepatic ketoreductase [21, 22]. 
Although the (R)-enantiomer has a longer half-life, it is less efficient and the modulation 
of its elimination does not have a significant impact on the coagulation [23–25]. There is 
a great discrepancy between tissue persistence of first generation and second generation 
of ARs. First-generation molecules have tissue persistence of few days while the second 
generation has tissue persistence of few weeks [26]. This point is a major concern for AR 
ecotoxicity.
Moreover, second-generation ARs (i.e. bromadiolone, difenacoum, brodifacoum, flocoumafen 
and difethialone) contain two asymmetric carbons systematically. Therefore, commercial sec-
ond-generation ARs are a mixture of two diastereoisomeric forms (1R,3R)(1S,3S)-isomers and 
(1R,3S)(1S,3R)-isomers with different pharmacokinetic properties. For each second-genera-
tion AR, there is systematically one diastereoisomeric form with a shorter half-life than the 
other one (Table 1) [20, 27]. Proportion between stereoisomers in commercial baits is defined 
by regulatory documents. For example, bromadiolone must be a mixture of more than 70 of 
trans-isomers and fewer than 30% of cis-isomers. These differences in half-life between ste-
reoisomers could be a fundamental point in the development of future more eco-friendly AR 
with modification of regulatory defined ratios.
2.3. Interest of anticoagulants in rodent population management
The first methods used to control rodent populations aim to kill them immediately. They were 
based on physical traps or on rapid killer molecules like strychnine. However, the neophobic 
behaviour of some rodents such as rats and their social organisation make these molecules 














Table 1. Half-lives of some anticoagulant rodenticide enantiomers.
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bait aversion in the rodent population [28, 29]. Conversely, the time to onset of anticoagulant 
action is sufficient to avoid that rodents link their symptoms and death to bait eating [29].
Moreover, the delay and the mechanism of action of ARs are the keystone of their safety of use 
comparatively to other rodenticides. Indeed, the delay allows the possibility to implement a 
treatment after an exposure to ARs and the mechanism of action can be easily bypassed which 
offers an efficient and safe antidotes, the vitamin K.
Nevertheless, some issues exist with anticoagulant rodenticides, first the resistance of some 
population to some AR molecules. This issue has led to the creation of the second generation 
of ARs, which are more efficient against resistant strains [30]. However, this generation is 
more persistent which involves other issues. This persistence extends the duration of anti-
dote treatment after exposure. Moreover, it entails a greater concentration of AR molecules in 
rodents after its death; thus, it might increase the risk of secondary poisoning of predators or 
scavenger animals. Consequently, to prevent poisoning of humans and animals, many actions 
have been implemented in the use of ARs.
2.4. Prevention of poisoning
In Europe, an anticoagulant rodenticide product can be registered either as a plant protec-
tion product or as a biocide. According to the kind of registration, restriction and modality of 
use are defined in order to prevent human and animal intoxication. Nevertheless, there are 
important differences on the modality and restriction among the European Member States. 
Here, we present some member state (MS) actions to prevent poisoning.
The majority of MS distinguishes the individual use of ARs and the professional use. 
Professional users are mainly the pest control operator, they have to be trained. In some coun-
tries like France or Italy, the sale of ARs is restricted for the individual user, thus, in France, 
individuals cannot buy more than 1.5 kg of AR bait. In other countries, like Germany, only 
trained professionals are allowed to use the second generation of ARs. Moreover, some mol-
ecules can be allowed as biocides and be forbidden as plant protection products.
The presentation of ARs is also regulated. Baits are presented as poisoned seed, paste or 
foam. Previously concentred products like tracking powder and oil concentrate were used 
but they have been forbidden in many states. Thus, concentrations of the current AR baits are 
of the order of few dozen to few hundred milligrams of active product per kilogram of bait. 
The concentration depends on the efficiency of the active molecule. The main consequence of 
the use of products with low concentration is that it is difficult to reach the lethal dose at once 
for mammal heavier than rodents such as cats, dogs or humans. Nevertheless, the high half-
life of some anticoagulants allows to reach this dose after a multi-exposure. The use of a bitter 
agent in bait is mandatory notably to avoid and limit exposure.
Finally, to avoid the exposure of untargeted species, in many states, baits have to be placed 
in secured bait stations. These stations have to be labelled to inform people on their content 
and on the action to perform in the case of exposure. Moreover, stations avoid the dispersion 
of baits which allows to control the consumption and they are waterproof, which prevent 
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water pollution. Nevertheless, some rodents are reluctant to enter in bait stations which might 
involve failing in pest control. In spite of all described elements to prevent exposures and 
intoxications of human and untargeted animals to ARs, many cases have been reported.
Therefore, some recent research makes effort to implement a third generation of ARs which 
is based on the stereochemistry concept, which would be efficient against resistant strains of 
rodents and be less persistent and thus less involved in secondary poisoning [20, 27].
3. Human exposures and intoxications
Intoxication with anticoagulant rodenticides is a major public health concern. The involve-
ment of poison control centres is crucial in the record of poisoning cases in both rural and 
urban areas. Besides, emergency departments report rare cases of intoxication by suicide or 
homicide. Most of these poisonings occur following accidental exposure, especially ingestion 
in children. Bleeding severity is highly variable, depending on the rodenticide exposure and 
on the delay between the exposure and patient management. The diagnosis relies on simple 
coagulation tests. Emergency department physicians should be aware of anticoagulant poi-
sonings since management differs according to the anticoagulant rodenticide including war-
farin or long-acting superwarfarin types.
3.1. Epidemiology
The incidence of poisoning with anticoagulant rodenticides is difficult to assess, mostly based 
on national registries. In the literature, cases associated with bleeding are published as case 
reports or small series, probably corresponding to the most severe ones.
In the annual report based on the US National Poison Data System and published by the 
American Association of Poison Control Centers, data related to long-acting superwarfarin- 
or warfarin-type rodenticides intoxication are given separately. Over the last 5-year period 
(2011–2015), the cumulated number of exposures is 44,095 for long-acting superwarfarin-
type and 1029 for warfarin-type drugs, with a single exposure in 97.3 and 95.6% of the cases, 
respectively [31–35]. Interestingly, the number of reported cases has slightly decreased since 
2008 (Figure 3) [36–38]. The mean prevalence of exposure over the last 5 years is 3.4% for long-
acting superwarfarin-type and 4.9% for warfarin-type drugs. The age distribution shows that 
children, especially those of less than 5 years old, are the most involved (Figure 4); only 9% of 
the reported cases are adults. Finally, clinical outcomes are reported (Figure 5). Remarkably, 
outcome is favourable in 93.6% of the cases, probably due to the limited ingested doses in 
relation to the bad taste of numerous rodenticides. The bitterness brought by the excipients 
in the currently marketed rodenticides considerably limits the ingested amounts, especially 
in young children. In cases associated with significant complications, severe bleedings are 
observed in less than 10% of cases, with fatal bleedings occurring in only eight patients among 
the 44,095 exposed patients during the last 5-year period in the USA. Overall, poisoning with 
rodenticides remains a rare cause of morbidities and fatalities [31–35].
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Figure 5. Distribution of the cases of poisoning with anticoagulant rodenticides reported by the American Association of 
Poison Control Centers in 2011–2015 according to the outcome.
Figure 3. Number of poisonings with anticoagulant rodenticides reported by the American Association of Poison 
Control Centers from 2008 to 2015. Black bars: intoxications with long-acting anticoagulant-type rodenticides; grey bars: 
intoxications with warfarin-type rodenticides.
Figure 4. Distribution of the cases of poisoning with anticoagulant rodenticides reported by the American Association of 
Poison Control Centers in 2011–2015 according to the patient age.
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3.2. Clinical outcomes and laboratory diagnosis
The threat in poisoning with rodenticides is the onset of severe bleeding. In humans like in 
rodents, anticoagulant rodenticides inhibit the enzyme vitamin K epoxide reductase complex 
(VKORC1) leading to the absence of vitamin K recycling, which is essential for the gamma-
carboxylation of vitamin K-dependent proteins in the hepatocytes, especially clotting pro-
thrombin, factors VII, IX and X. This leads to impaired functioning of gamma-carboxylated 
vitamin-K-dependent factors due to their inability to bind activated platelets. Given the half-
lives of coagulation in humans, i.e. from 6 hours for FVII to ~60 hours for prothrombin, the 
onset of hypocoagulability and the risk of bleeding are delayed after the exposure to roden-
ticides. The risk of bleeding depends on the severity of the hypocoagulability state induced 
by rodenticides and on the duration of hypocoagulability. The spectrum of bleeding is wide: 
extended unexplained spontaneous ecchymosis, epistaxis, hematoma, bleeding from the gas-
tro-intestinal or the genitourinary tract as well as intra-cerebral bleeding are reported [39–46].
The diagnosis of rodenticide intoxication has to be considered for any patient with prolonged 
prothrombin time (increased INR), prolonged activated partial prothrombin time; the vitamin 
K-dependent factor II, VII, X, IX coagulant activities are decreased while factor V coagulant 
activity and the fibrinogen level are normal [41, 43, 47, 48]. Liver dysfunction, cholestasis and 
severe starvation can be ruled out by normal liver enzymes and serum albumin concentration. 
Moderate to severe anaemia can be present, depending on the severity of bleeding. Special 
attention and high clinical suspicion are required in patients with apparent negative history 
of warfarin treatment. The diagnosis of rodenticide intoxication should be suspected when 
the international normalised ratio (INR) strongly fluctuates on vitamin K therapy, especially 
while high doses of vitamin K are required. The accessibility to anticoagulant rodenticides 
should be checked; monitoring of persons who deal with rodenticides in their home or work-
place, especially those suffering from dementia or psychiatric disorders, is necessary [49]. The 
intoxication can be confirmed by the identification and measurement of the rodenticides in 
plasma by specific assays [42, 45, 50].
3.3. Principles of poisoning management
Acute life-threatening complications can be prevented with timely intervention. Immediate 
administration of high doses of phytomenadione (vitamin K1) and/or factor prothrom-
bin complex concentrate (30 UI/kg FIX) can successfully reverse the anticoagulant effects 
of anticoagulant rodenticides. With tissue half-lives estimated at between 16 and 220 days, 
 reversal of superwarfarin toxicity is a long-term issue. Therefore, long-term daily treatment 
for  several weeks of phytomenadione is necessary. Treatment courses averaged 168 days. To 
avoid  re-bleeding, close monitoring of INR is necessary. Adjunctive haemostatic therapy with 
recombinant factor VIIa and prothrombin complex concentrate has been used [50–54].
4. Overview on animal exposures and intoxications
To assess the importance of animal intoxications, it is important to discriminate two situa-
tions: the domestic animals and the wildlife. Concerning wildlife, the evaluations of exposures 
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and intoxications are often realised during focused scientific campaign and are often based 
on contamination studies or after an important mortality in wildlife. In domestic animal, 
besides the scientific campaign, there are, in some countries, animal specialised poison con-
trol centres, which can provide data on exposure, intoxications and linked symptoms.
In this part, it is important to take account of the differences between exposure and intoxication. 
Concerning exposure, it is the fact to take a dose of anticoagulants, it can be suspected by an 
owner who sees its animal eating baits, sometimes without knowing what the active substance 
is, or find in wildlife by pinpointing the presence of VKA in the sample. Intoxication is when 
the active substance induced clinical signs. This distinction is fundamental in the study of VKA 
toxicology. Indeed, to observe intoxication, the exposure dose and the delay of action has to be 
sufficient. This issue is discussed further concerning the wildlife exposure/intoxication studies.
4.1. Domestic animals
In France, two control poison centres are specialised in animals. The most important in terms 
of call number is the ‘Centre National d' Informations Toxicologiques Vétérinaires (CNITV)’ 
which responds to questions from owners or veterinarians on a 24-hour/7 day basis. We used 
this important database to assess the importance of VKA exposures and intoxications in 
domestic animals.
The data of the last 9 years have been analysed. During this period, the CNITV has received 
about 150,000 calls. Each month, 10.73% (CI 10.41-11.06) of solicitations are about VKA expo-
sure or intoxication. Moreover, about whole VKA appeal is on domestic animals (99.2%). 
Appeals accrue from veterinary (69%) and owner (29%) mainly.
During the analysis of data, an important seasonality of the calls concerning VKAs has been 
pinpointed (Figure 6). Significant (p < 0.05) increases of the number of calls for VKA exposure 
are observed during the months of August, September and October followed by a significant 
decrease of appeal numbers from December to April, which is surprising. Indeed, based on 
our experience, the periods when people apply rodenticides in cities are at the beginning of 
winter (late November) and at the beginning of spring (March), when rodents are active and 
when the scarcity of food encourages rodents to eat baits. Conversely, during summer and 
the beginning of autumn, rodents can find many sources of food; consequently, they are less 
likely to eat baits, which increase the risk that baits are eaten by untargeted animals, notably 
dogs. However, summer is also the time when there is less human in cities and this element 
with a lenient weather encourages the presence of rodents outside where they are more visi-
ble. In response, cities and individuals might increase the number of baits, which is unfavour-
able for the rodent population management and rocket up the risk of pet exposures to VKA.
More generally, data pinpoint a trend reversal; before September 2013, the number of cases 
has significantly increased with a slope of 3.9% per annum (p < 0.0001) whereas after this date 
it has significantly decreased of 10.5% per annum (p < 0.0001). The increase trend has to be 
relativised as the total number of calls significantly increases during this period. However, 
after 2013, the total number of calls was stable (p = 0.13). Consequently, a significant decrease 
in the number of calls for VKAs after 2013 is confirmed. We hypothesise that the source of 
this diminution is the evolution of the regulation. Indeed, regulation has enforced the use of 
secured bait station since 2013, which seems to reduce the exposure of domestic species.
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Pets and more specifically dogs are over represented (Figure 7). This might be explained by 
the lack of use of secured bait station by private individuals and by the behaviour of dogs. 
Poisoning is mainly accidental even if some malicious poisoning are reported (2.03%). The 
proportion of suspected malicious case concerning cats is significantly higher than for the 
general case. Indeed, cats and dogs represent, respectively, 19.14 and 63.64% of malicious 
reports. These uses of anticoagulant rodenticides with harmful intent against animals but 
also against humans have led to restrict the sale of rodenticides in some countries such as 
Italy [55].
Concerning molecules, in 22% of calls, the exact molecule is not identified. Nevertheless, 
exposures or intoxications with one of the six molecules authorised are reported, they are 
difenacoum, difethialone, brodifacoum, bromadiolone, chlorophacinone and coumatetralyl, 
which represent, respectively, 23, 18, 10, 9, 3 and 2% of the calls for AR. It is significant that 
the four main anticoagulants are second-generation ARs. This was predictable because first-
generation ARs are less efficient on resistant strains of rodents consequently main ARs sold 
belong to the second generation.
Figure 6. (A): Evolution of monthly calls for VKA exposure over time. Grey curve is the running means over 5 months. 
Dark lines are linear regression from January 2008 to September 2013 and from September 2013 to February 2017. (B) 
Variation of the number of calls for VKA exposure with the precedent month, values are represented as the mean of 
observed variations for the concerned month over the period 2008–2016 and its 95% confidence interval.
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The consequences of an exposure without intoxication are completely different for pets and 
farm animals. Indeed, for pets when an exposure occurs, the aim is to prevent intoxication. In 
farm animals, more than intoxication prevention, the presence of anticoagulant molecules in 
products such as meat, eggs or milk has to be considered. Further, we discuss issues of ARs 
in pets then in farm animals.
In pets, depending on caller, the circumstances of appeal are different. Indeed, 90% of calls 
from individuals report exposure without intoxication, whereas the proportion of this cir-
cumstance drops significantly to 75% when it is a call from a veterinary (p < 0.0001). This can 
be easily understood, if an animal shows a symptom, the owner priority is to bring it to the 
veterinarian to be healed. Differences according to species are also pinpointed. In dogs, 81% 
of calls for AR exposure do not report symptoms versus 62% in cats (p < 0.0001). The source of 
this distinction may be the detection of the exposure, which is earlier in dogs. Moreover, cats 
may be more prone to be secondary exposed to ARs from intoxicated rodents and this kind 
of exposure is not visible by the owner. It should be noted that according to the low doses of 
bait and to the difference between the toxic doses for a rodent versus a cat, a large number of 
intoxicated rodents should be eaten to induce intoxication.
In dogs and cats, when an exposure is suspected and when it is possible, the best way to pre-
vent intoxication is to induce vomiting in the first hour after the exposure. If medicines are not 
available, it is possible to use 10 volume hydrogen peroxide. Hydrogen peroxide solution can 
be given orally to animals at 1 mL for every 5 kg of weight. Be careful, salt must not be used 
to induce vomiting. Indeed, excess of salt can cause fatal hypernatremia [56].
Sometimes, even the exposure is uncertain or the absorption of VKA after vomiting is 
unknown, to confirm exposure, two means are currently tested by our team: the dosing of 
VKAs in plasma and their dosing in faeces. The difficulty of dosing in plasma is that for some 
VKAs, the presence in the plasma is temporary then VKAs are stored in liver. Therefore, dosing 
Figure 7. Percentage of species concerned by calls on VKA.
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in plasma is often associated with false-negatives. The dosing of VKA in faeces seems to be 
more reliable with an excretion that can be detected for several weeks.
As there is not any well-described toxicity dose, it is important to follow the possible effect 
of AR in order to prevent serious intoxication. Moreover, there is no correlation between the 
dose of VKA and the symptom severity [57]. Today, the gold standard to diagnose VKA 
intoxication is the prothrombin time [58]. It is advised realising a prothrombin time about 48 
hours after the suspected exposure [59]. If the prothrombin time is elevated then a treatment 
has to be initiated. Other methods such as vitamin K clotting factor concentration measure-
ment are explored to detect AR effects sooner. Factor VII seems to be a good candidate as its 
half-life after a VKA administration is the shorter [60].
If no treatment is given, symptoms may appear after 2–6 days [57, 58]. Symptoms are the 
classic signs of coagulopathy, which may be pinpointed by owner as bleeding, pale mucous 
membrane, haematomas, haematuria or haematemesis as well as their consequences on ani-
mal general condition as lameness, depression or lethargy [57, 58, 61]. Owing to intrathoracic 
bleeding, respiratory distress occurs frequently in anticoagulant intoxications [62–64].
Animals exposed with an elevation of prothrombin time after exposure or with AR-linked 
symptoms have to receive vitamin K
1
 supplementation as long as the recycling mechanism is 
inhibited. Vitamin K
1
 is given per os daily with a dose of 5 mg/kg of body weight. The duration 
of the VKA inhibition depends on the pharmacokinetics of AR molecule with huge differences 
between molecules. Thus, the duration of treatment after an exposure to the first-generation 
AR is estimated to 3 weeks versus 5–7 for the second generation. Nevertheless, there is a lack 
of studies to support these durations of treatment. Thus, a treatment can be initiated during 
at least 1 month then stopped during 48 hours. After 2 days of treatment discontinuation, 
the vitamin K regeneration mechanism can be assessed by measuring prothrombin time. If 
prothrombin time is elevated, treatment has to be replicated until a new assessment of regen-
eration mechanism else, the treatment can be arrested. Vitamin K
3
 is inefficient to treat VKA 
intoxication. The treatment of symptomatic animals may require fresh plasma to reconstitute 
the pool of clotting factors urgently, moreover, in this case, it is recommended initiating the 
vitamin K treatment by an intravenous administration. If there is a proper compliance of the 
vitamin K treatment, the prognostic is excellent [57].
In farm animals, when an AR exposure occurs, the safety of the product has to be consid-
ered. Little information is available on the contamination of food following AR exposure. 
Nevertheless, many methods have been implemented to assess the residues in foodstuffs 
[65, 66]. Concerning meat, it has been shown that VKA molecules are present in muscle 
after exposure and that the cooking does not influence their activities [67]. Likewise, VKA 
molecules are also present in eggs after hen exposure, and are still detected in eggs 14 days 
after exposure [68]. Concerning the milk, it has been observed an excretion of VKA in human 
milk when a VKA is used as medication for the mother [69]. Consequently, it might be sup-
posed that the same occurs in animals. Thus, when an animal is exposed, its litter should be 
separated of its mother and fed with relevant artificial milk. If separation is not possible or 
if diagnostic is late, litter should be supplemented with vitamin K
1
. Concerning foodstuffs 
provided by an exposed animal, their management would be done in accordance with rel-
evant authority.
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4.2. Wildlife exposures and intoxication
Wildlife expositions or intoxications to ARs have been reported around the world for many 
mammals such as minks [70], bobcats [71], stoats and weasels [72], foxes [73, 74] and boars 
[67] and as well for many birds [75–77]. Exposition of fish was reported near an island where 
an eradication of rodent with brodifacoum was performed and the risk for human through 
the consumption appeared very low [78].
These intoxications may be primary when non-target species eat directly the bait. It is the 
case when baits are directly available without protection or when they are washed away and 
diluted in sea or river. In Spain, a study on water and soil samples revealed no imminent 
environmental risk in treated areas with chlorophacinone and brodifacoum [79]. However, 
the use of secured bait stations prevents this kind of exposition.
The secondary exposition occurs when a scavenger or a predator eats an exposed rodent. It is 
the most described exposition of wildlife to ARs and the most difficult to prevent. Many factors 
may influence the level of secondary exposition. First, due to the bait appetence, rodents can 
eat more AR than necessary to lead to their death, which might increase their concentration 
in AR. Moreover, if rodent is resistant to ARs, this phenomenon might be amplified. Indeed, 
a resistant rodent eats twice to fivefold more AR than susceptible rodent [1]. After the onset 
of symptoms in rodents, their behaviour evolves. They increase their activity during the day 
and stay longer in uncovered area, which enhances the risk to be hunted by predators [1]. The 
delayed action of ARs, inherent to its mechanism, allows rodents to eat several times the LD50 
dose between the first bait intake and the death [1] and may as well increase the risk of second-
ary exposition. Pesticide usage has been correlated with non-target wildlife exposition [74, 75], 
and the intensity of treatment was related to incidence on local fox populations in France [80]. 
Finally, the diet is certainly going to influence secondary exposition and species like raptors, 
foxes and mustelids largely feeding on rodents when abundant are consequently the most at 
risk, as demonstrated for the red kite (Milvus milvus) [81]. The removal of visible rodent bod-
ies helps to reduce the risk of secondary exposition [82] but is not always possible because of 
landscape limited access and in the case of aerial application [1]. Mitigation measures have 
been considered to protect predatory species but new approaches are still required [82].
Persistence and toxicity of the molecule are key factors. They depend on the used active ingre-
dient [26, 83]. Historically, second-generation ARs had been designed to be more persistent 
and toxic on resistant strain. Thus, secondary poisonings of wildlife associated with the use 
of second generation are more often reported. But the development of new ARs recently pro-
posed is based on the stereochemistry of second-generation ARs with reduced persistence but 
equivalent toxicity might greatly decrease the level of secondary exposition [20].
They are two types of consequences of the exposition of wildlife to ARs. First, if the species 
is eaten by human [67, 78], the consequences are comparable to those discussed for farm ani-
mals. Second, if the exposition is sufficiently important, it might lead to intoxication of the 
animals and to its death, which can be problematic mainly for endangered species. The rate 
of exposure of non-target species has often been evaluated, and summed liver concentrations 
above a limit of 0.2 mg/kg associated with clinical signs (i.e. macroscopic haemorrhages with 
no trauma) have been statistically characterised as representative of a high-risk toxic threshold 
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[84]. According to these criteria, hepatic concentrations above 0.2 mg/kg have been associated 
with mortalities in raptors and small mustelids from Denmark [85], in raptors and hedgehogs 
from Mediterranean region of Spain [86], in six raptor species from Canary Islands, Spain [77].
It is difficult to discriminate a simple exposition and intoxication in wildlife. Indeed, as 
well as in domestic animal, toxic doses are not well described for all species. Moreover, the 
majorities of exposition studies are performed on dead animal, and as the lesion induced 
by ARs is not specific, so it might be difficult to conclude to its implications. Less than 10% 
of exposed and dead birds have been confirmed to be intoxicated by ARs [1, 87]. Currently, 
there are no reports of a significant incidence of ARs on non-targeted species populations [82]. 
Nevertheless, impact of ARs on wildlife has to be more monitored in order to limit the impact 
of rodent population management. The probable future design of eco-friendly baits with new 
isomer ratio will change the need the way AR hepatic residues are monitored. The recently 
described multi-residue LC-MS/MS method [88] is an appropriate tool to start investigating 
second-generation AR diastereoisomer proportions in non-target wildlife and to evaluate 
their respective persistence in predators.
5. Conclusion
Anticoagulant rodenticides are a keystone of the rodent population management. Like other 
poisons, there is a risk of human or non-targeted species poisoning. The wide use of antico-
agulant rodenticides near human living space and agriculture space involves an important 
exposure of humans and domestic animals. Nevertheless, since few years, many risk mitiga-
tion measures have been taken and the number of exposure in humans and domestic animals 
has decreased. Moreover, in contrast to the majority of chemical biocide, anticoagulant roden-
ticides have an effective antidote, the vitamin K. Consequently, anticoagulant poisoning is 
rarely fatal. However, the impact of anticoagulant rodenticides on wildlife is least well known 
and deserves more investigation.
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